S3 Ep47: Understanding the Pendulum Swing in CLL Research Over the Last Decade
Cancer Horizons15 Okt 2020

S3 Ep47: Understanding the Pendulum Swing in CLL Research Over the Last Decade

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Matthew Davids about the results of a clinical trial that assessed the addition of Copiktra (duvelisib) to fludarabine, cyclophosphamide and Rituxan (rituximab) in the frontline setting for patients with chronic lymphocytic leukemia (CLL) aged 65 years and younger.

Davids, director of clinical research in the Lymphoma Program at Dana-Farber Cancer Institute in Boston, also provides insight into the current CLL landscape and discusses what he refers to as a swing in the pendulum of CLL research over the last 10 years, and how that pendulum swing has created a slight gap for the assessment of younger patients with the disease.

“As the novel agents have come of age here in the last decade, that as a field, we've gotten better at kind of shifting the studies into older patients,” Davids explained in an interview with CURE®. “… One kind of gap that I can see right now in the field is that because the pendulum has swung, I think appropriately toward the older population in terms of the trials, we actually do seem to have fewer trials kind of focused on the young fit patients compared to the old days. And so that is an area I think of interest for sure is the novel agent-based approaches in the young patients.”

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(295)

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berg...

31 Des 202514min

S7 Ep1: The Importance of Spotting Endometrial Cancer

S7 Ep1: The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

18 Mar 202510min

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

17 Sep 202419min

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another ca...

4 Mar 20247min

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, an...

4 Mar 202410min

S6 Ep20: FDA Approvals from February 2024

S6 Ep20: FDA Approvals from February 2024

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers. ...

23 Feb 20246min

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tum...

19 Feb 20249min

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered researc...

12 Feb 20247min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
forskningno
villmarksliv
rekommandert
liberal-halvtime
tomprat-med-gunnar-tjomlid
vett-og-vitenskap-med-gaute-einevoll
sinnsyn
rss-nysgjerrige-norge
fjellsportpodden
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
rss-rekommandert
diagnose
dekodet-2
rss-skogkurs-podden
nevropodden
smart-forklart
rss-overskuddsliv